Clinical Trial

Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Name: Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07458659)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CART-BCMA

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A Phase 1b clinical trial to evaluate the safety and efficacy of BCMA-targeted CAR T-cell therapy in Thai patients with relapsed or refractory multiple myeloma.

Trial Details

NCT Number	NCT07458659
Lead Sponsor	Chulalongkorn University Collaborators: King Chulalongkorn Memorial Hospital
Conditions	Relapsed/Refractory Multiple Myeloma (MM)
Enrollment	3 participants
Start Date	2026-06-01
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-09